Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The overall objectives are to explore the safety and efficacy of Reverse Transcriptase Inhibitors Tenofovir (TDF)/ Emtricitabine (FTC) administered in AGS affected children 2 to 18 years of age.
Epistemonikos ID: 2a45ec66308c5e1dbd421d5e461faa67160f2ff8
First added on: May 21, 2024